Nurix Therapeutics (NASDAQ: NRIX) reports fiscal Q3 2025 results

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. filed a Form 8-K to report that it issued a press release announcing its financial results for the fiscal quarter ended August 31, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference. The company states that the information under Item 2.02, including Exhibit 99.1, is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal liability purposes.

00015495952025FYfalse00015495952025-10-092025-10-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 9, 2025

___________________________________________

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________

Delaware			001-39398			27-0838048
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)
1700 Owens Street, Suite 205 San Francisco, California						94158
(Address of Principal Executive Offices)						(Zip Code)

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code) 

N/A

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			NRIX			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On October 9, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended August 31, 2025. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.						Exhibit Title or Description
99.1						Press Release dated October 9, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NURIX THERAPEUTICS, INC.
Date: October 9, 2025			By:			/s/ Arthur T. Sands
						Arthur T. Sands, M.D., Ph.D.
						President and Chief Executive Officer

3

FAQ

What event is Nurix Therapeutics (NRIX) reporting in this Form 8-K?

Nurix Therapeutics is reporting that it issued a press release announcing its financial results for the fiscal quarter ended August 31, 2025, and is furnishing that release as an exhibit.

Which fiscal period do the reported results cover for Nurix Therapeutics (NRIX)?

The reported financial results cover Nurix Therapeutics’ fiscal quarter ended August 31, 2025.

Where can investors find the detailed quarterly results for Nurix Therapeutics (NRIX)?

The detailed quarterly results are contained in the press release furnished as Exhibit 99.1 to this Form 8-K.

Is the Nurix Therapeutics (NRIX) earnings press release considered filed with the SEC?

No. The company specifies that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

What exhibits are included with this Nurix Therapeutics (NRIX) Form 8-K?

The Form 8-K includes Exhibit 99.1, the press release dated October 9, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed this Nurix Therapeutics (NRIX) Form 8-K?

The Form 8-K was signed on behalf of Nurix Therapeutics, Inc. by Arthur T. Sands, M.D., Ph.D., the company’s President and Chief Executive Officer.